Relieves bronchospasm. ANDA 214531, held by The Ritedose. Albuterol Sulfate.
As of Nov 20, 2026, ANDA 214531 (Albuterol Sulfate), held by The Ritedose, was first approved by FDA on Dec 28, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 28, 2021 | Original application | Approved | None posted |
| Albuterol SulfateEQ 0.021% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 0.042% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| May 8, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 28, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters